- Home
- SCYX vs TPST Comparison
SCYX vs TPST Comparison
Compare SCYX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- TPST
- Stock Information
- Founded
- SCYX 1999
- TPST 2011
- Country
- SCYX United States
- TPST United States
- Employees
- SCYX N/A
- TPST N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- TPST Health Care
- Exchange
- SCYX Nasdaq
- TPST Nasdaq
- Market Cap
- SCYX 28.5M
- TPST 33.0M
- IPO Year
- SCYX 2014
- TPST N/A
- Fundamental
- Price
- SCYX $0.70
- TPST $7.54
- Analyst Decision
- SCYX
- TPST Hold
- Analyst Count
- SCYX 0
- TPST 3
- Target Price
- SCYX N/A
- TPST $30.00
- AVG Volume (30 Days)
- SCYX 187.5K
- TPST 94.0K
- Earning Date
- SCYX 08-11-2025
- TPST 08-11-2025
- Dividend Yield
- SCYX N/A
- TPST N/A
- EPS Growth
- SCYX N/A
- TPST N/A
- EPS
- SCYX N/A
- TPST N/A
- Revenue
- SCYX $2,630,000.00
- TPST N/A
- Revenue This Year
- SCYX $410.22
- TPST N/A
- Revenue Next Year
- SCYX $248.83
- TPST N/A
- P/E Ratio
- SCYX N/A
- TPST N/A
- Revenue Growth
- SCYX N/A
- TPST N/A
- 52 Week Low
- SCYX $0.66
- TPST $5.35
- 52 Week High
- SCYX $2.21
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- SCYX 41.70
- TPST 56.78
- Support Level
- SCYX $0.67
- TPST $7.13
- Resistance Level
- SCYX $0.74
- TPST $8.75
- Average True Range (ATR)
- SCYX 0.04
- TPST 0.47
- MACD
- SCYX 0.00
- TPST 0.12
- Stochastic Oscillator
- SCYX 10.15
- TPST 54.17
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.